Zymeworks Inc. is a global biotechnology company. Co. is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). We show 27 historical shares outstanding datapoints in our ZYME shares outstanding history coverage, used to compute ZYME market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ZYME market cap history over the course of time is important for investors
interested in comparing ZYME's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ZYME versus a peer is one thing; comparing
ZYME market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ZYME can fluctuate over the course of history.
With this page we aim to empower investors researching ZYME by allowing them to research the ZYME market cap history. |
Free ZYME Email Alerts:
Video: The Importance of Market Cap
